Corona Remedies IPO Analyzed
Corona Remedies, a pharmaceutical company focusing on women’s health and related treatments, recently completed its Initial Public Offering (IPO). Investors showed strong interest, bidding for significantly more shares than initially offered. This analysis provides a key overview of the IPO’s performance and the company’s current standing.
Key Points
- Strong investor demand: Bids exceeded initial share offering by 137%.
- IPO size: Total offer of Rs 655.37 crore by existing shareholders.
- Promoter Ownership: Promoters hold 72.5% of the company’s shares post-IPO.
- Significant Revenue: Women’s health and cardio-diabeto account for 53.19% revenue.
- Anchor Investor Funding: Rs 194.85 crore raised from anchor investors.
- Strong Financials: Reported Rs 46.20 crore net profit for the period.
The IPO involved an offer of 45.71 million shares. However, investors placed bids for 62.65 billion shares, meaning the demand was 137.04% higher than the original offering. This exceptional interest suggests confidence in the company’s growth potential and the market’s view of its therapeutic areas.
Existing shareholders, including Dr. Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, and Sepia Investments, were selling their shares through this IPO. The company is aiming to raise approximately Rs 655.37 crore. The price band for the IPO was set between Rs 1,008 and Rs 1,062 per share.
Corona Remedies specializes in developing, manufacturing, and marketing pharmaceutical products. They concentrate on areas like women’s health, cardiovascular health, diabetes, pain management, and urology. Their largest revenue stream comes from women’s health and cardiovascular medications, accounting for 53.19% of their business as of Q1 FY26.
As of June 30, 2025, the company had built a diverse portfolio with 71 brands across these therapeutic areas. Importantly, 96.34% of their revenue comes from India, with just a small percentage—3.66%—from exports. The company’s strongest market presence is in western India, specifically in states like Gujarat, Maharashtra, and Madhya Pradesh.
To further bolster the IPO, Corona Remedies secured an additional Rs 194.85 crore from 17 anchor investors prior to the IPO’s launch on December 5, 2025. The company reported strong financial performance for the three months ending September 30, 2025, with a consolidated net profit of Rs 46.20 crore and total sales of Rs 346.54 crore.
This IPO demonstrates significant investor confidence in Corona Remedies’ strategic focus and growth opportunities within the Indian pharmaceutical market.
